La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Supernus Pharmaceuticals Crescita futura

Future criteri di controllo 3/6

Si prevede che Supernus Pharmaceuticals aumenterà gli utili e i ricavi rispettivamente del 61.3% e 7.3% all'anno, mentre si prevede che l'EPS crescerà del 60.7% all'anno.

Informazioni chiave

61.3%

Tasso di crescita degli utili

60.7%

Tasso di crescita dell'EPS

Pharmaceuticals crescita degli utili	23.6%
Tasso di crescita dei ricavi	7.3%
Rendimento futuro del capitale proprio	n/a
Copertura analitica	Low
Ultimo aggiornamento	07 Aug 2024

Aggiornamenti recenti sulla crescita futura

Recent updates

Supernus Pharmaceuticals' (NASDAQ:SUPN) Conservative Accounting Might Explain Soft Earnings

Aug 19

Supernus Pharmaceuticals: So-So Neuroscience Portfolio, With ADHD Standout

Jul 02

Subdued Growth No Barrier To Supernus Pharmaceuticals, Inc.'s (NASDAQ:SUPN) Price

Apr 24

These 4 Measures Indicate That Supernus Pharmaceuticals (NASDAQ:SUPN) Is Using Debt Reasonably Well

Oct 19

Supernus stock falls 12.6% after FDA declines to approve Parkinson’s disease treatment

Oct 10

Supernus Pharmaceuticals: Deep Expertise In CNS, Eyes On Qelbree Launch And Parkinson Portfolio

Aug 19

Supernus Pharmaceuticals' (NASDAQ:SUPN) Soft Earnings Are Actually Better Than They Appear

Aug 16

Supernus: A Work In Progress

Jul 29

Supernus: New Beginnings

Mar 28

Brokers Are Upgrading Their Views On Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) With These New Forecasts

Dec 02

Is Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Trading At A 34% Discount?

Nov 30

Is Supernus Pharmaceuticals (NASDAQ:SUPN) Using Too Much Debt?

Oct 19

Is Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Trading At A 49% Discount?

Aug 31

Previsioni di crescita degli utili e dei ricavi

NasdaqGM:SUPN - Stime future degli analisti e dati finanziari passati (USD Millions )
Data	Ricavi	Guadagni	Flusso di cassa libero	Liquidità dell'operazione	Avg. Numero di analisti
12/31/2026	691	38	139	N/A	4
12/31/2025	626	-49	99	218	4
12/31/2024	622	16	91	206	4
6/30/2024	630	5	154	155	N/A
3/31/2024	597	-16	100	100	N/A
12/31/2023	608	1	111	111	N/A
9/30/2023	611	26	93	94	N/A
6/30/2023	634	43	71	72	N/A
3/31/2023	668	52	162	162	N/A
12/31/2022	667	61	116	117	N/A
9/30/2022	659	38	138	138	N/A
6/30/2022	630	57	120	120	N/A
3/31/2022	601	73	94	95	N/A
12/31/2021	580	53	125	127	N/A
9/30/2021	564	82	108	110	N/A
6/30/2021	571	100	117	120	N/A
3/31/2021	556	111	163	166	N/A
12/31/2020	520	127	135	138	N/A
9/30/2020	477	129	145	150	N/A
6/30/2020	424	118	177	182	N/A
3/31/2020	402	116	114	119	N/A
12/31/2019	393	113	142	143	N/A
9/30/2019	408	106	131	132	N/A
6/30/2019	409	105	156	157	N/A
3/31/2019	404	103	134	135	N/A
12/31/2018	409	111	128	129	N/A
9/30/2018	381	99	131	132	N/A
6/30/2018	359	87	107	109	N/A
3/31/2018	335	73	N/A	128	N/A
12/31/2017	302	57	N/A	115	N/A
9/30/2017	276	58	N/A	103	N/A
6/30/2017	253	104	N/A	92	N/A
3/31/2017	228	97	N/A	83	N/A
12/31/2016	215	91	N/A	67	N/A
9/30/2016	196	84	N/A	64	N/A
6/30/2016	179	26	N/A	35	N/A
3/31/2016	163	18	N/A	32	N/A
12/31/2015	147	14	N/A	35	N/A
9/30/2015	135	11	N/A	18	N/A
6/30/2015	118	5	N/A	14	N/A
3/31/2015	112	5	N/A	-6	N/A
12/31/2014	93	-11	N/A	-24	N/A
9/30/2014	72	-37	N/A	-40	N/A
6/30/2014	50	-59	N/A	-51	N/A
3/31/2014	21	-89	N/A	-60	N/A
12/31/2013	12	-92	N/A	-58	N/A
9/30/2013	3	-83	N/A	-65	N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: La crescita prevista degli utili di SUPN ( 61.3% all'anno) è superiore al tasso di risparmio ( 2.5% ).

Guadagni vs Mercato: Si prevede che gli utili di SUPN ( 61.3% all'anno) cresceranno più rapidamente del mercato US ( 15.1% all'anno).

Guadagni ad alta crescita: Si prevede che gli utili di SUPN cresceranno in modo significativo nei prossimi 3 anni.

Ricavi vs Mercato: Si prevede che il fatturato di SUPN ( 7.3% all'anno) crescerà più lentamente rispetto al mercato US ( 8.8% all'anno).

Ricavi ad alta crescita: Si prevede che il fatturato di SUPN ( 7.3% all'anno) crescerà più lentamente di 20% all'anno.

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

ROE futuro: Dati insufficienti per determinare se il Return on Equity di SUPN è previsto essere elevato tra 3 anni

Supernus Pharmaceuticals Crescita futura

Future criteri di controllo 3/6

Informazioni chiave

Aggiornamenti recenti sulla crescita futura

Supernus Pharmaceuticals, Inc. Raises Financial Guidance for the Full Year 2024

Supernus Pharmaceuticals, Inc. Reiterates Financial Guidance for the Full Year 2024

Consensus EPS estimates fall from profit to US$0.01 loss

Consensus EPS estimates increase by 44%, revenue downgraded

Consensus EPS estimates upgraded to US$0.06 loss

Consensus estimates of losses per share improve by 58%

Recent updates

Supernus Pharmaceuticals' (NASDAQ:SUPN) Conservative Accounting Might Explain Soft Earnings

Supernus Pharmaceuticals, Inc. Announces SPN-830 Apomorphine Infusion Device NDA Accepted for Review by FDA

Supernus Pharmaceuticals, Inc. Raises Financial Guidance for the Full Year 2024

Supernus Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 06, 2024

Supernus Pharmaceuticals: So-So Neuroscience Portfolio, With ADHD Standout

First quarter 2024 earnings released: EPS: US$0.002 (vs US$0.31 in 1Q 2023)

Supernus Pharmaceuticals, Inc. Reiterates Financial Guidance for the Full Year 2024

Supernus Pharmaceuticals, Inc., Annual General Meeting, Jun 14, 2024

Supernus Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 08, 2024

Subdued Growth No Barrier To Supernus Pharmaceuticals, Inc.'s (NASDAQ:SUPN) Price

Consensus EPS estimates fall from profit to US$0.01 loss

Insider notifies of intention to sell stock

Consensus EPS estimates increase by 44%, revenue downgraded

Supernus Pharmaceuticals: Moving Through An 'Inflection Year'

Founder exercised options and sold US$469k worth of stock

Supernus Pharmaceuticals, Inc. Announces Intangible Asset Impairment Charges for the Quarter Ended December 31, 2023

Supernus Pharmaceuticals, Inc. Announces Intangible Asset Impairment Charges for the Quarter Ended December 31, 2023

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Supernus Pharmaceuticals, Inc. to Report Q4, 2023 Results on Feb 27, 2024

Insider notifies of intention to sell stock

Consensus EPS estimates upgraded to US$0.06 loss

Founder exercised options and sold US$331k worth of stock

Consensus estimates of losses per share improve by 58%

Investor sentiment improves as stock rises 18%

Supernus Pharmaceuticals, Inc. Revises Earnings Guidance for the Full Year 2023

Third quarter 2023 earnings: EPS in line with analyst expectations despite revenue beat

Supernus Pharmaceuticals, Inc. Announces SPN-830 Apomorphine Infusion Device NDA Accepted for Review by FDA

Consensus EPS estimates fall by 64%

Supernus Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 08, 2023

New minor risk - Insider selling

Consensus EPS estimates fall by 64%

Supernus Pharmaceuticals, Inc. Resubmits NDA for SPN-830 Apomorphine Infusion Device

Supernus Pharmaceuticals, Inc. Announces New Qelbree®? Data Showing Improvement in ADHD Symptoms

Founder exercised options and sold US$539k worth of stock

Insider notifies of intention to sell stock

Supernus Pharmaceuticals, Inc. Appoints Bethany L. Sensenig to Board of Directors

Consensus EPS estimates fall by 40%

New minor risk - Shareholder dilution

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Supernus Pharmaceuticals, Inc. Reiterates Earnings Guidance for the Full Year 2023

Supernus Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 08, 2023

Supernus Pharmaceuticals, Inc.(NasdaqGM:SUPN) dropped from Russell 2000 Value-Defensive Index

Consensus estimates of losses per share improve by 84%

Founder exercised options and sold US$547k worth of stock

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Supernus Pharmaceuticals, Inc. Revises Earnings Guidance for the Year 2023

We Think Supernus Pharmaceuticals (NASDAQ:SUPN) Can Stay On Top Of Its Debt

Senior Vice President of Quality recently sold US$172k worth of stock

Consensus EPS estimates fall from profit to US$0.033 loss

Full year 2022 earnings: EPS and revenues miss analyst expectations

Supernus Pharmaceuticals, Inc. to Report Q4, 2022 Results on Feb 28, 2023

Founder exercised options and sold US$446k worth of stock

Does Supernus Pharmaceuticals (NASDAQ:SUPN) Have A Healthy Balance Sheet?

Insider exercised options and sold US$149k worth of stock

Insider notifies of intention to sell stock

Independent Chairman of the Board exercised options to buy US$311k worth of stock.

Founder exercised options and sold US$439k worth of stock

Consensus forecasts updated

Founder exercised options and sold US$343k worth of stock

Insufficient new directors

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Supernus Pharmaceuticals, Inc. Revises Earnings Guidance for the Full Year 2022

Supernus Pharmaceuticals, Inc. to Report Q3, 2022 Results on Nov 08, 2022

These 4 Measures Indicate That Supernus Pharmaceuticals (NASDAQ:SUPN) Is Using Debt Reasonably Well

Price target decreased to US$35.33

Supernus Pharmaceuticals, Inc. Provides Regulatory Update on SPN-830

Supernus stock falls 12.6% after FDA declines to approve Parkinson’s disease treatment

Supernus Pharmaceuticals: Deep Expertise In CNS, Eyes On Qelbree Launch And Parkinson Portfolio

Supernus Pharmaceuticals' (NASDAQ:SUPN) Soft Earnings Are Actually Better Than They Appear